Skip to main content
MRK
NYSE Life Sciences

默克的Keytruda联合疗法显著改善卵巢癌生存率

feedReported by Reuters
Sentiment info
Positive
Importance info
8
Price
$121.41
Mkt Cap
$300.173B
52W Low
$73.31
52W High
$125.14
Market data snapshot near publication time

summarizeSummary

默克宣布，其畅销抗癌药Keytruda与紫杉醇联合使用，显著改善了铂类耐药性复发性卵巢癌患者的总体生存率。这一积极的临床试验结果是默克的一个重要发展，特别是在公司最近的10-K文件中警告了由于专利到期和IRA价格设定，Keytruda的未来收入可能会下降。Keytruda的疗效扩展到新的或扩大的适应症，如卵巢癌，可能有助于抵消预期的收入压力，并扩大该药物的市场潜力。交易者现在将关注进一步的监管提交和潜在的标签扩展，这可能会为默克的长期增长前景提供显著的提振。

在该公告发布时，MRK的交易价格为$121.41，交易所为NYSE，所属行业为Life Sciences，市值约为$3001.7亿。 52周交易区间为$73.31至$125.14。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed MRK - Latest Insights

MRK
Apr 24, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Merck Clears Key Antitrust Hurdle for Terns Pharmaceuticals Acquisition
Sentiment: Positive
View Wiseek Article
MRK
Apr 21, 2026, 11:50 AM EDT
Source: Reuters
Importance Score:
8
US FDA Approves Merck's New Combination HIV Treatment
Sentiment: Positive
View Wiseek Article
MRK
Apr 21, 2026, 6:51 AM EDT
Source: Reuters
Importance Score:
8
Merck-Eisai Cancer Therapy Fails Late-Stage Study Goals
Sentiment: Negative
View Wiseek Article
MRK
Apr 20, 2026, 7:29 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
FDA Grants Priority Review to Merck, Pfizer Bladder Cancer Drug Combo
Sentiment: Positive
View Wiseek Article
MRK
Apr 13, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
8
Merck Actively Pursues Acquisitions to Bolster Pipeline Ahead of Keytruda Patent Expiration
Sentiment: Positive
View Wiseek Article
MRK
Apr 08, 2026, 4:25 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Merck Projects Over $70B Pipeline Opportunity, Details Executive Changes and Annual Meeting Proposals
Sentiment: Positive
View Wiseek Article
MRK
Mar 30, 2026, 4:04 PM EDT
Source: Wiseek News
Importance Score:
9
Merck's Oral PCSK9 Inhibitor Enlicitide Cuts LDL-C 64.6% in Phase 3, Outperforming Competitors
Sentiment: Positive
View Wiseek Article
MRK
Mar 30, 2026, 11:48 AM EDT
Source: Reuters
Importance Score:
9
Merck's Oral PCSK9 Inhibitor Enlicitide Decanoate Slashes LDL-C by 64.6%, Earns FDA Priority Voucher
Sentiment: Positive
View Wiseek Article
MRK
Mar 29, 2026, 11:49 AM EDT
Source: Reuters
Importance Score:
8
Merck's Winrevair Hits Phase 2 Endpoint, Advancing to Registrational Phase 3 for Pulmonary Hypertension
Sentiment: Positive
View Wiseek Article
MRK
Mar 25, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Merck Acquires Terns Pharma, Bolstering Hematology Pipeline with Novel CML Candidate TERN-701
Sentiment: Positive
View Wiseek Article